TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36414316

Group type: EXPERIMENTAL
Intervention: Combination therapy of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ramipril/benazepril) and sodium-glucose cotransporter-2 (SGLT2) inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment with any of these agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and SGLT2 inhibitor
Number of subjects: 0
Study: 36414332

Group type: EXPERIMENTAL
Intervention: Incidence of new-onset AF in the adult population (≥20 years)
Number of subjects: 411387

Group type: EXPERIMENTAL
Intervention: Prevalence of AF in the adult population
Number of subjects: 411387

Group type: EXPERIMENTAL
Intervention: Prevalence of AF by sex
Number of subjects: 411387

Group type: EXPERIMENTAL
Intervention: Incidence and prevalence of AF in patients older than 75 years
Number of subjects: 411387

Group type: EXPERIMENTAL
Intervention: Age-adjusted incidence of AF
Number of subjects: 411387
Study: 36414425

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT), 148 patients (58%) underwent MT
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (patients with high NWU, ≥11.4%)
Number of subjects: 254
Study: 36414969

Group type: EXPERIMENTAL
Intervention: Immediate urinary catheter removal (at the end of surgery)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Early urinary catheter removal (within 24 hours post-surgery)
Number of subjects: 216
Study: 36414993

Group type: EXPERIMENTAL
Intervention: Confirmed menstrual tracking data
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Black participants
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Class 1 obesity (BMI 30-34.9)
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Class 2 obesity (BMI 35-39.9)
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Class 3 obesity (BMI >40)
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Class 3 obesity
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Polycystic ovary syndrome
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Hyperthyroidism
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Hypothyroidism
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Endometriosis
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Cervical dysplasia
Number of subjects: 18875

Group type: COMPARATOR
Intervention: Fibroids
Number of subjects: 18875
Study: 36415000

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 354

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 354
Study: 36415178

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided laser ablation (EUS-LA)
Number of subjects: 20
Study: 36415604

Group type: EXPERIMENTAL
Intervention: Four doses of SARS-CoV-2 vaccine (vaccine group)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Three doses of SARS-CoV-2 vaccine (control group)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Hybrid immunity (three vaccine doses followed by COVID-19)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Three and four doses of SARS-CoV-2 vaccine (both groups)
Number of subjects: 914
Study: 36415883

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36416136

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (PCSK9i)
Number of subjects: 696
Study: 36416787

Group type: EXPERIMENTAL
Intervention: Early KRT initiation
Number of subjects: 4880
Study: 36416805

Group type: EXPERIMENTAL
Intervention: 5G-based remote MCE
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional MCE
Number of subjects: 20
Study: 36416874

Group type: EXPERIMENTAL
Intervention: CART19/20 cells (36 × 10^6 to 165 × 10^6 cells)
Number of subjects: 10
Study: 36416880

Group type: EXPERIMENTAL
Intervention: Cancer-specific meditation app prototype used daily (≥70 minutes per week) for 4 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Optional web-based poststudy interview
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Weekly and poststudy questionnaires
Number of subjects: 36
Study: 36417356

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dual-energy x-ray absorptiometry (DXA)
Number of subjects: 42
Study: 36417367

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 36417675

Group type: EXPERIMENTAL
Intervention: epithelium-off accelerated corneal cross-linking (CXL, 9 mW/cm2, 10 min, 5.4 J/cm2)
Number of subjects: 41
Study: 36417764

Group type: EXPERIMENTAL
Intervention: Wide-diameter bone-anchored hearing implant (loaded at 3 weeks after surgery)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Wide-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Previous-generation small-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Wide-diameter bone-anchored hearing implant
Number of subjects: 51
Study: 36418119

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (protocol-specified antidepressants)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200
Study: 36418122

Group type: EXPERIMENTAL
Intervention: Hospital-acquired pressure injuries (PIs)
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Braden score and prior length of ICU stay
Number of subjects: 1312
Study: 36418127

Group type: EXPERIMENTAL
Intervention: Face mask sampling with polyvinyl alcohol test strips for 2 hours daily over at least 7 days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-administered nasal swabs and optional finger prick blood samples.
Number of subjects: 0
Study: 36418170

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36418515

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 157
Study: 36418966

Group type: EXPERIMENTAL
Intervention: suPAR ≥ 8.0 ng/mL in patients with infection
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: suPAR ≥ 8.0 ng/mL in patients without infection
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Inability to answer questions relating to pain in patients who developed sepsis
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: suPAR ≥ 8.0 ng/mL in patients who developed sepsis
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Inability to answer questions relating to specific symptoms in patients with infection
Number of subjects: 871
Study: 36418965

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (various classes including penicillins, fluoroquinolones, and macrolides)
Number of subjects: 9886

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid and levofloxacin
Number of subjects: 9886

Group type: EXPERIMENTAL
Intervention: History of cardiac ischemia
Number of subjects: 9886

Group type: EXPERIMENTAL
Intervention: History of asthma
Number of subjects: 9886

Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 9886

Group type: EXPERIMENTAL
Intervention: History of COPD
Number of subjects: 9886

Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 9886
Study: 36419331

Group type: EXPERIMENTAL
Intervention: Culture-based prophylaxis
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Empirical prophylaxis with oral ciprofloxacin (control group)
Number of subjects: 1288
Study: 36419530

Group type: EXPERIMENTAL
Intervention: 600 mg/day gabapentin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1,800 mg/day gabapentin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 36419980

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Impaired executive cognitive function
Number of subjects: 351
Study: 36420712

Group type: EXPERIMENTAL
Intervention: Atezolizumab (ATZ)
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 4400
Study: 36421007

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance -PCI (HA-PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: HA-PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy added to chemotherapy
Number of subjects: 0
Study: 36422666

Group type: EXPERIMENTAL
Intervention: Digital Radiography (DR) system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Computed Radiography (CR) system
Number of subjects: 24
Study: 36422811

Group type: EXPERIMENTAL
Intervention: Routine use of pre-operative imaging (CT scans in 55.77% of patients) during the COVID-19 pandemic
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no routine imaging)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Comparison of negative appendicectomy rates between groups
Number of subjects: 104
Study: 36422852

Group type: EXPERIMENTAL
Intervention: Roflumilast cream 0.3% applied once daily for 14 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Roflumilast cream 0.3%
Number of subjects: 26
Study: 36422983

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (aboBoNT-A)
Number of subjects: 49
Study: 36423376

Group type: EXPERIMENTAL
Intervention: HDF assessment in HFpEF patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Impaired systolic peak
Number of subjects: 68
Study: 36423588

Group type: EXPERIMENTAL
Intervention: Danicopan (Factor D Inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36423805

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption during follow-up
Number of subjects: 650

Group type: COMPARATOR
Intervention: No alcohol consumption
Number of subjects: 650
Study: 36423925

Group type: EXPERIMENTAL
Intervention: Incident non-COVID-19 ARI
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: Incident COVID-19 (prior to omicron variant)
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: Incident COVID-19 (post omicron variant)
Number of subjects: 2312
Study: 36423968

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (PRU)
Number of subjects: 11714
Study: 36424257

Group type: EXPERIMENTAL
Intervention: 4vHPV vaccine
Number of subjects: 65606

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 65606
Study: 36424269

Group type: EXPERIMENTAL
Intervention: Low muscle strength
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low muscle mass
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Association between low muscle mass and cachexia
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Association between sarcopenia and cachexia
Number of subjects: 64
Study: 36424360

Group type: EXPERIMENTAL
Intervention: Therapies targeting signaling pathways in CAFs
Number of subjects: 0
Study: 36424612

Group type: EXPERIMENTAL
Intervention: Technology-aided rehabilitation devices (5 devices trialed for 30-45 minutes each)
Number of subjects: 7
Study: 36424628

Group type: EXPERIMENTAL
Intervention: Conteltinib (CT-707) at doses of 50 to 800 mg QD
Number of subjects: 64
Study: 36424756

Group type: EXPERIMENTAL
Intervention: TaqIA allele status
Number of subjects: 29
Study: 36425296

Group type: EXPERIMENTAL
Intervention: Upper arm transcutaneous oximetry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forearm transcutaneous oximetry
Number of subjects: 0
Study: 36425320

Group type: EXPERIMENTAL
Intervention: Primary SMICH patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Single ICH patients
Number of subjects: 37
Study: 36426287

Group type: EXPERIMENTAL
Intervention: Nivolumab (N)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nivolumab-Ipilimumab combination (NI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Overall study
Number of subjects: 31
Study: 36426808

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 weekly for 12 weeks followed by dose-dense epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) for four 2-week cycles
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel followed by dose-dense EC
Number of subjects: 55
Study: 36427020

Group type: EXPERIMENTAL
Intervention: Ulixertinib 600 mg PO BID (de-escalated to 450 mg BID) plus gemcitabine and nab-paclitaxel (GnP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ulixertinib plus GnP
Number of subjects: 18
Study: 36427162

Group type: EXPERIMENTAL
Intervention: Caplacizumab 10 mg administered daily during plasma exchange and for 30 days afterward, in combination with immunosuppressive treatment
Number of subjects: 21
Study: 36427173

Group type: EXPERIMENTAL
Intervention: Novel diagnostics (including WHO symptom screen, digital chest radiograph, sputum for Xpert MTB/Rif Ultra)
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Screening for HIV, diabetes (HbA1c), chronic lung disease (spirometry), hypertension, and anaemia at baseline
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Statistical analyses including assessment of diagnostic accuracy
Number of subjects: 2100
Study: 36427183

Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy (aromatase inhibitor or fulvestrant) as first-line treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line treatment effectiveness
Number of subjects: 0
Study: 36427229

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard care for NSTI (including surgery and broad-spectrum antibiotics)
Number of subjects: 95
Study: 36427227

Group type: EXPERIMENTAL
Intervention: iCanChange (iCC) + modified Early Intervention Services (EIS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Early Intervention Services (EIS)
Number of subjects: 100
Study: 36427234

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) along with chemotherapy, supervised by a qualified kinesiologist, including endurance and resistance training at moderate intensity 3 times a week for 6 months.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) along with chemotherapy.
Number of subjects: 186

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group).
Number of subjects: 186
Study: 36427239

Group type: EXPERIMENTAL
Intervention: Motivation Makes the Move! intervention
Number of subjects: 89
Study: 36427481

Group type: EXPERIMENTAL
Intervention: UNDERPIN-ICU multicomponent non-pharmacological nursing intervention program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Facilitating factors identified in the application of the UNDERPIN-ICU program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hindering factors identified in the application of the UNDERPIN-ICU program
Number of subjects: 30
Study: 36427645

Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes, delivering 6750 cGy to the prostate and 4500 cGy to the pelvic lymph nodes in 25 daily fractions.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes.
Number of subjects: 54
Study: 36428084

Group type: EXPERIMENTAL
Intervention: Discordantly graded aortic valve stenosis (DGAS) after adjustment for pressure recovery
Number of subjects: 1353
Study: 36428100

Group type: EXPERIMENTAL
Intervention: SUMMIT study nodule management algorithm with a threshold volume of 200 mm
Number of subjects: 0
Study: 36428272

Group type: EXPERIMENTAL
Intervention: Opioid consumption in patients with no opioid-related adverse effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid consumption corresponding to one point on a cumulated opioid-related adverse event 0-10 scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid-related adverse effects for consecutive opioid dose intervals of 2 mg iv morphine equivalents
Number of subjects: 0
Study: 36428744

Group type: EXPERIMENTAL
Intervention: High-Ma-bTMB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ma-bTMB
Number of subjects: 0
Study: 36428784

Group type: EXPERIMENTAL
Intervention: Pre-operative NLR <2.7
Number of subjects: 786

Group type: COMPARATOR
Intervention: Pre-operative NLR ≥2.7
Number of subjects: 786
Study: 36429387

Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 78
Study: 36433685

Group type: EXPERIMENTAL
Intervention: SCB-2019 vaccine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 36433753

Group type: EXPERIMENTAL
Intervention: Fast spindle band power fluctuations during NREM sleep
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Clustering level of fast spindles
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Mean size of spindle clusters
Number of subjects: 147
Study: 36433829

Group type: EXPERIMENTAL
Intervention: isatuximab 20 mg/kg QW/Q2W
Number of subjects: 28
Study: 36433837

Group type: EXPERIMENTAL
Intervention: E-learning for PGY-1 residents
Number of subjects: 170
Study: 36434329

Group type: EXPERIMENTAL
Intervention: Patients with cryptogenic ischemic stroke
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stroke-free controls
Number of subjects: 30
Study: 36434376

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPC-calculated SQI
Number of subjects: 0
Study: 36434392

Group type: EXPERIMENTAL
Intervention: Combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1)
Number of subjects: 21
Study: 36434554

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day) and Avelumab (800 mg on days 1 and 15)
Number of subjects: 50
Study: 36434580

Group type: EXPERIMENTAL
Intervention: Healthier Wealthier Families (HWF) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 36434602

Group type: EXPERIMENTAL
Intervention: LETSGO intervention (nurse-led consultations with eHealth technology)
Number of subjects: 0
Study: 36434733

Group type: EXPERIMENTAL
Intervention: Red Yeast Rice (RYR)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 36434779

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 4018

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 4018
Study: 36435158

Group type: EXPERIMENTAL
Intervention: Ambulatory transcutaneous carbon dioxide monitoring (tcCO2)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 39
Study: 36435266

Group type: EXPERIMENTAL
Intervention: BAY2586116 (160 μg) nasal spray
Number of subjects: 12

Group type: COMPARATOR
Intervention: BAY2586116 (3 μg) nasal drops
Number of subjects: 12

Group type: COMPARATOR
Intervention: BAY2586116 (30 μg) nasal drops
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 12
Study: 36435336

Group type: EXPERIMENTAL
Intervention: PyRadiomics
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: SOPHiA Radiomics
Number of subjects: 148
Study: 36435633

Group type: EXPERIMENTAL
Intervention: Nasal vaccines
Number of subjects: 0
Study: 36435928

Group type: EXPERIMENTAL
Intervention: Neural crest tumour treatment
Number of subjects: 6
Study: 36435949

Group type: EXPERIMENTAL
Intervention: New formula for calculating Lp(a)-C from molar measurement of Lp(a) (Lp(a) nmol/L × 0.077 = Lp(a)-C mg/dL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional formula for estimating Lp(a)-C as 30% of measured Lp(a) mass
Number of subjects: 0
Study: 36435952

Group type: EXPERIMENTAL
Intervention: Higher survivor perceived relationship quality
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Higher spouse perceived relationship quality
Number of subjects: 90
Study: 36436013

Group type: EXPERIMENTAL
Intervention: Fetal pancreas size measured at 20-22 weeks and 24-28 weeks
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 109
Study: 36436128

Group type: EXPERIMENTAL
Intervention: Initiation of endocrine therapy (ET)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Non-persistence of endocrine therapy (ET)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Factors associated with non-initiation
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Factors associated with non-persistence
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Chemotherapy and symptom burden
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Recurrence associated with non-persistence
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Shared decision-making
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Confidence in decision-making
Number of subjects: 693
Study: 36436259

Group type: EXPERIMENTAL
Intervention: Self-efficacy (T1)
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: General anxiety (T1)
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: COVID-19 cases/deaths (T0)
Number of subjects: 1256
Study: 36436279

Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SL-RNA detection in CSF
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood at month 12
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood at month 18
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SL-RNA detection for relapse detection
Number of subjects: 97
Study: 36436320

Group type: EXPERIMENTAL
Intervention: Fampridine treatment for 14 days
Number of subjects: 14
Study: 36436423

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET) with genomic testing using 70-gene and 80-gene signatures
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 67